Because ovarian clear cell carcinoma is relatively rare, the signals from the patient's specimens were compared with a reference cohort of 19 breast carcinomas (a mixture of hormone receptor–positive/HER2-negative, HER2-positive, and triple-negative). This evidence concerns the gene ERBB2 and breast carcinoma.